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Abstract
In contrast to the corresponding mouse and rat orthologs, the human histamine H4 receptor
(hH4R) shows extraordinarily high constitutive activity. In the extracellular loop (ECL), re-
placement of F169 by V as in the mouse H4R significantly reduced constitutive activity. Sta-
bilization of the inactive state was even more pronounced for a double mutant, in which, in
addition to F169V, S179 in the ligand binding site was replaced by M. To study the role of
the FF motif in ECL2, we generated the hH4R-F168A mutant. The receptor was co-
expressed in Sf9 insect cells with the G-protein subunits Gαi2 and Gβ1γ2, and the mem-
branes were studied in [3H]histamine binding and functional [35S]GTPγS assays. The po-
tency of various ligands at the hH4R-F168A mutant decreased compared to the wild-type
hH4R, for example by 30- and more than 100-fold in case of the H4R agonist UR-PI376 and
histamine, respectively. The high constitutive activity of the hH4R was completely lost in the
hH4R-F168A mutant, as reflected by neutral antagonism of thioperamide, a full inverse ago-
nist at the wild-type hH4R. By analogy, JNJ7777120 was a partial inverse agonist at the
hH4R, but a partial agonist at the hH4R-F168A mutant, again demonstrating the decrease in
constitutive activity due to F168A mutation. Thus, F168 was proven to play a key role not
only in ligand binding and potency, but also in the high constitutive activity of the hH4R.
Introduction
Among the extracellular loops (ECLs) of class A GPCRs, the ECL2 is the largest and the most
diverse one [1]. ECL2 contributes to ligand recognition, binding, selectivity, allosteric modula-
tion and activation of GPCRs [1, 2]. In the absence of ligand, ECL2 is a putative “gatekeeper”
[1], assumed to adopt an open conformation giving access to the binding pocket. Ligand bind-
ing can induce a partially closed conformation. Massotte et al. [3] and Klco et al. [4] suggested
that ECL2 is involved in interactions stabilizing the inactive state of the receptor. However, spe-
cific amino acid sequences in the ECL2 of some GPCRs may stabilize active receptor states and
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play a role in constitutive activity [5, 6]. For instance, ECL2 was reported to be involved in the
activation of the human muscarinic M3 (hM3R) [7] and the human histamine H4 receptor
(hH4R) [8, 9]. Additionally, the disulfide bond between cysteines in both ECL2 and transmem-
brane domain 3 (TM3, Fig. 1) is of relevance for GPCR function, as shown, for example, for
rhodopsin [10], the M1R [11], the β2-adrenergic (β2AR) [12] and the gonadotropin releasing
hormone receptor (GnRH-R) [13]. Furthermore, ECL2 contributes to the high affinity state of
the β2AR [12]. Apart from modifying ligand-free states, ECL2 was shown to have an impact on
ligand binding and selectivity [11, 14, 15].
Constitutive activity describes the ability of a GPCR to produce a biological response in the
absence of a bound ligand [16, 17]. The degree of constitutive activity reflects the shift of the
basal equilibrium from the inactive to the active state of a GPCR. Inverse agonists stabilize the
inactive receptor conformation and are therefore capable of reducing or blocking constitutive
activity. Consequently, constitutive activity of a GPCR is a prerequisite to determine inverse
agonism and vice versa [18].
In contrast to the rodent orthologs mH4R and rH4R, high constitutive activity is characteris-
tic of the hH4R [8, 9, 19, 20]. H4R species orthologs are well suited for exploring the molecular
basis of this phenomenon, because there are not too many differences between the sequences
in ECL2. Site-directed mutagenesis within the ECL2 of the hH4R compared to the mH4R re-
vealed that the hH4R-F169V mutant is similar to the mH4R in terms of ligand affinities and po-
tencies, suggesting that F169 is a key amino acid for differential interactions of certain
agonists with the human and mouse H4R orthologs [21]. The assumption that F169 also con-
tributes to constitutive activity was confirmed by investigations on the mutants hH4R-F169V
and F169V+S179M [9]. F169 alone or in concert with S179 (TM5, ligand binding site) plays a
major role in stabilizing a ligand-free active state of the hH4R. The constitutive activity of the
hH4R-F169V mutant was significantly reduced compared to the wild-type hH4R. In particular,
the inverse agonistic effect of thioperamide decreased.
Figure 1. View from the extracellular side into the binding pocket of the human H4R. Homology model
[9] based on the crystal structure of the hH1R inactive state [24]. The FF motif (F168 and F169), pointing to
the ligand binding pocket, is illustrated as green balls and sticks, the disulfide bond connecting TM3 with
ECL2 as yellow sticks and the binding pocket as a semitransparent surface colored in magenta. Generated
with PyMOLMolecular Graphics System, Version 1.6 (Schrödinger LLC, Portland, OR, USA).
doi:10.1371/journal.pone.0117185.g001
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F169 is part of the FF-motif, which is located on top of the ligand binding pocket (Fig. 1)
and conserved in a number of class A GPCRs, e.g., the hβ2AR, hH3R, monkey H4R, canine H4R
and the hM2R. Instead of the FF-motif, other GPCRs, such as the hβ1AR, hM1R, hM3R, hM4R,
and the hM5R, as well as several H4R species orthologs, e.g., pig H4R, guinea pig H4R, mouse
H4R and rat H4R, contain only one phenylalanine, which is located in a position corresponding
to that of F168 in the hH4R. In these cases, in the adjacent position a non-aromatic hydropho-
bic amino acid such as valine or leucine is present instead of phenylalanine.
Crystal structures provide information on the position and the conformation of the FF-
motif. The side chain of the first phenylalanine (in case of the hM2R also of the second one
[22]) points into the ligand binding pocket. In the hβ2AR and in the hH1R, the second phenyl-
alanine (and a tyrosine in case of hH1R) is oriented in the opposite direction [23, 24]. Our re-
cent results on the contribution of F169 to the constitutive activity of the hH4R suggested that
F168 plays a significant role as well. In order to investigate the influence of F168 on both recep-
tor activation and ligand binding [9], we generated and characterized the hH4R-F168A mutant
in comparison to the wild-type and the recently described hH4R-F169V mutant. The mutant
receptors were expressed in Sf9 insect cells, and membrane preparations were used for satura-
tion binding with [3H]histamine and functional studies were performed with inverse agonists,
neutral antagonists and agonists in the [35S]GTPγS assay (Fig. 2).
Materials and Methods
Materials
The pcDNA3.1 vector containing the hH4R sequence was from the cDNA Resource Center at
the University of Missouri-Rolla (Rolla, MO, USA). The pVL1392-SF-H4R-His6 plasmid was
constructed as described previously [19, 25]. Baculovirus encoding Gαi2 was kindly provided by
Dr. A. G. Gilman (Department of Pharmacology, University of Southwestern Medical Center,
Dallas, TX USA). Recombinant baculovirus encoding the Gβ1γ2 subunits was a kind gift of
Dr. P. Gierschik (Department of Pharmacology and Toxicology, University of Ulm, Ulm, Ger-
many). PfuUltra II DNA polymerase was from Agilent (Böblingen, Germany). The DNA prim-
ers for polymerase chain reaction (PCR) were fromMWG-Biotech (Ebersberg, Germany).
Restriction enzymes were from New England Biolabs (Ipswich, MAUSA). Gradient gels (8–16%,
12 well nUView gels) as well as the peqGOLD protein marker I, used for Coomassie brilliant blue
R staining, were from Peqlab (Erlangen, Germany). UR-PI294 and UR-PI376 were synthesized
as described [26, 27]. Thioperamide, JNJ7777120 and VUF8430 were synthesized according to
Lange et al. [28], Jablonowski et al. [29], and Lim et al. [30]. Isoloxapine [31, 32] was synthesized
and provided by Dr. S. Gobleder (Institute of Pharmacy, University of Regensburg, Regensburg,
Germany). All other H4R ligands were from Tocris (Avonmouth, Bristol, UK). For chemical
structures of the investigated compounds cf. Fig. 2. UR-PI376 (10 mM) was dissolved in 50%
(v/v) dimethyl sulfoxide (DMSO) and dilutions were prepared in 20% (v/v) DMSO in order to at-
tain a final DMSO concentration of 2% (v/v) in each well. Stock solutions (10 mM) of clozapine
or isoloxapine were prepared in Millipore water containing 3 and 2 mol equivalents of HCl, re-
spectively. All other stock solutions were prepared with Millipore water. [35S]GTPγS (1000 Ci/
mmol) and [3H]histamine (25 Ci/mmol) were fromHartmann Analytic (Braunschweig, Ger-
many). All other reagents were from standard suppliers and of the highest purity available.
Methods
Site-directed mutagenesis of the hH4R. The preparation of the hH4R-F168A cDNA was es-
sentially performed as described for the hH4R-F169V mutant [9]. To introduce the F168A mu-
tation into the pVL1392-SF-hH4R-His6 expression vector a site-directed mutagenesis PCR was
ECL2 of the hH4R: Role in Ligand Binding and Constitutive Activity
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performed using the following primers 5’-GGT AGT GAA TGT GAA CCT GGA GCC TTT
TCG GAA TGG TAC ATC C-3’ and 5’-G GAT GTA CCA TTC CGA AAA GGC TCC AGG
TTC ACA TTC ACT ACC-3’.
Cell culture, generation of recombinant baculoviruses and membrane preparation. Cell
culture and generation of high-titer recombinant baculovirus stocks [25] as well as the co-
infection of Sf9 cells with high-titer baculovirus stocks encoding Gαi2, Gβ1γ2 and the respective
H4R [8] were performed as described recently [9]. Membrane preparations were performed ac-
cording to Gether et al. [33] in the presence of 0.2 mM phenylmethylsulfonyl fluoride, 1 mM
Figure 2. Structures of the investigated H4R ligands.
doi:10.1371/journal.pone.0117185.g002
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ethylenediaminetetraacetic acid (EDTA), 10 μg/mL leupeptin and 10 μg/mL benzamidine as
protease inhibitors. Prepared membranes were resuspended in binding buffer (75 mM Tris/
HCl, 12.5 mMMgCl2,1 mM EDTA, pH 7.4) and stored at −80°C in 0.5 or 1.0 mL aliquots.
SDS-PAGE and Coomassie staining. Prior to incubation at 30°C for 15 min, the respective
membrane preparation (15 µg protein) as well as a negative control (Sf9 cells transfected with
pVL1392 devoid of an insert) were loaded onto the gel as well as 5 µL of the protein marker I
[9]. A 2x sample buffer without urea was used for sample preparation. The gels were stained in
a solution of 0.1% Coomassie brilliant blue G250 in 50% methanol and 10% acetic acid and
subsequently destained with a solution containing 13% methanol and 7% acetic acid.
[3H]histamine saturation binding experiments. The experiments were performed in 96-well
plates [9]. Each well contained 43–133 µg of protein in a total volume of 100 µL. For saturation
binding, membranes were incubated in binding buffer containing [3H]histamine (1–200 nM) and
0.2% (w/v) BSA at room temperature under shaking at 200 rpm for 60 min. Non-specific binding
was determined in the presence of 10 µM unlabeled histamine. Filtration through glass microfiber
filters (Whatman GF/C), pretreated with polyethylenimine 0.3% (w/v), using a Brandel 96 sample
harvester (Brandel, Unterföhring, Germany), was performed to separate unbound frommem-
brane-associated [3H]histamine. After three washing steps with binding buffer, filter pieces were
punched out, transferred into 96-well sample plates 1450–401 (Perkin Elmer, Rodgau, Germany),
and 200 µL of scintillation cocktail (Rotiscint Eco plus, Roth, Karlsruhe, Germany) per well were
added before incubation in the dark under shaking at 200 rpm. Radioactivity was measured with
a Micro Beta2 1450 scintillation counter (Perkin Elmer, Rodgau, Germany).
[35S]GTPγS binding assay. Membranes were thawed, centrifuged for 10 min at 4°C and
13,000 g and carefully resuspended in binding buffer [9]. Experiments were performed in 96-
well plates in a total volume of 100 µL per well. Each well contained 7–19 µg of protein (7–10
µg for hH4R, 10–14 µg for hH4R-F169V and 10–19 µg for hH4R-F168A), 1 µM GDP, 100 mM
NaCl, 0.05% (w/v) bovine serum albumine (BSA), 20 nCi of [35S]GTPγS (0.2 nM) and ligand at
concentrations as indicated in the results section. Antagonism was determined in the presence
of histamine (10-fold EC50 at the respective receptor). Nonspecific binding was determined in
the presence of 10 µM unlabeled GTPγS. After incubation under shaking at 200 rpm at room
temperature for 2 h, bound [35S]GTPγS was separated from free [35S]GTPγS by filtration
through glass microfibre filters using a 96-well Brandel harvester. The filters were washed three
to four times with binding buffer (4°C), dried over night and impregnated with meltable scintil-
lation wax prior to counting with a Micro Beta2 1450 scintillation counter.
Protein concentrations of all membrane preparations were determined with the Bio-Rad
DC protein assay kit (München, Germany) in one experiment. Because UR-PI376 had to be
dissolved in 20% DMSO, the water control as well as the full agonist histamine (α = 1.0), to
which all other ligands were referenced, were also dissolved in 20% DMSO in case of this li-
gand. Concentration-response curves were constructed by fitting the data according to the four
parameter logistic fit (variable slope), and analyzed with the Prism 5.01 software (GraphPad,
San Diego, CA USA). Kb values were calculated according to the Cheng-Prusoff equation [34].
All values are given as mean ± SEM of at least three independent experiments performed in
triplicate. Significances were calculated using one-way analysis of variance (ANOVA), followed
by Bonferroni’s multiple comparison test.
Results
Receptor expression
Human histamine H4 receptor wild-type as well as mutants (hH4R-F169V and hH4R-F168A)
were expressed in Sf9 insect cells together with G-protein subunits Gαi2 and Gβ1γ2 [9, 35]. As
ECL2 of the hH4R: Role in Ligand Binding and Constitutive Activity
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previously shown by SDS PAGE and western blots [9], the wild-type or mutated H4 receptors
migrated with an apparent molecular weight of 39 kDa and the Gαi2 protein with an apparent
molecular weight of 41 kDa. The hH4R wild-type and both mutant receptors, hH4R-F169V and
hH4R-F168A, respectively as well as the Gαi2 protein were expressed at comparably high levels
as becomes obvious from Coomassie stained SDS gels (Fig. 3). However, specific binding of [3H]
histamine to the hH4R-F168Amutant was too low to determine the Kd value (highest concentra-
tion of radioligand used: 200 nM). By contrast, the wild-type hH4R as well as the hH4R-F169V
mutant revealed high specific binding as described previously (cf. [9], saturation binding curves
are depicted in Figures S3A and B in the Supporting Information of the respective publication).
Functional analysis of wild-type and mutant H4 receptors
Functional data—intrinsic activities (α), potencies (pEC50) and antagonist activities (pKb)—
were determined in the [35S]GTPγS assay using standard agonists as well as inverse agonists
Figure 3. Coomassie stained SDS gels.Membrane proteins of Sf9 insect cells, coexpressing the
respective receptor as indicated and Gαi2 as well as Gβ1γ2 were separated on 8–16% polyacrylamide
gradient gels. All samples were analyzed on the same gel. In the interest of clarity, the membranes prepared
from Sf9 cells transfected with pVL1392 devoid of an insert (negative control) were placed next to the
molecular weight standard.
doi:10.1371/journal.pone.0117185.g003
ECL2 of the hH4R: Role in Ligand Binding and Constitutive Activity
PLOS ONE | DOI:10.1371/journal.pone.0117185 January 28, 2015 6 / 14
and neutral antagonists (Fig. 2 and Table 1). For comparison, data from the hH4R-F169V mu-
tant [9] are included in Table 1. Upon maximal stimulation with histamine, the amounts of
bound [35S]GTPγS were significantly different, decreasing in the order hH4R wild-type>
hH4R-F169V> hH4R-F168A (Fig. 4). The effect of the inverse agonist thioperamide reflects
constitutive activity of wild-type and mutant receptors. The response to thioperamide de-
creased in the order hH4R> hH4R-F169V> hH4R-F168A (Fig. 4), i. e., constitutive activity
was highest at the hH4R wild-type, significantly smaller at the hH4R-F169V mutant [9] and ab-
sent at the hH4R-F168A mutant, where thioperamide acted as a neutral antagonist.
The normalized concentration-response curves of histamine (maximal effect of histamine at
the respective receptors, set to 100%) are depicted in Fig. 5A. The potency of histamine de-
creased from the hH4R via the hH4R-F169V to the hH4R-F168A mutant by more than two or-
ders of magnitude (Fig. 5A and Table 1). The same holds for the full agonist UR-PI294 [27]
with a decrease in potency by about 1.5 orders of magnitude from the hH4R to the hH4R-
F168A mutant without significant changes of intrinsic activity (Fig. 5B).
The potency of clozapine and the structurally related isoloxapine decreased from the hH4R
via the hH4R-F169V to the hH4R-F168A mutant with maximal shift of the curve by one order
of magnitude (Fig. 5C, D). The intrinsic activity of clobenpropit, a partial agonist, and UR-
PI376 [26], a full agonist at the hH4R significantly decreased at the two mutants (Fig. 5E, F).
For clobenpropit, despite reduced maximal responses, no significant changes of the potency
were observed. By contrast, the potency of UR-PI376 was by more than one order of magnitude
lower at the mutants than at the wild-type.
Compared to the wild-type hH4R, the potencies and intrinsic activities of the partial ago-
nists immepip and VUF8430 were not significantly affected by the hH4R-F169V mutation [9].
By contrast, at the hH4R-F168A mutant, the potencies decreased by about two orders of mag-
nitude (Fig. 5G, H).
Figure 4. Maximal agonistic effects of histamine (light blue) andmaximal inverse agonistic effects of
thioperamide (yellow) in the [35S]GTPγS-assay.Data represent [35S]GTPγS [pmol/mg protein] specifically
bound to wild-type and mutated H4Rs. The line separating light blue and yellow bar represents [
35S]GTPγS
binding in the absence of ligand.
doi:10.1371/journal.pone.0117185.g004
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Inverse agonism of thioperamide was highest at the hH4R, significantly lower at the hH4R-
F169V [9] and not detectable at the hH4R-F168A mutant (Fig. 5I). Instead, thioperamide be-
haved as a neutral antagonist with a pKb value of 7.97. JNJ7777120 was a partial inverse agonist
at the hH4R but, surprisingly, acted as a partial agonist at the hH4R-F169V and hH4R-F168A
mutants (Fig. 5J).
Discussion
Potencies of ligands at mutated H4 receptors
With respect to potency at mutant H4 receptors, except thioperamide, the investigated ligands
are divided in two groups. The first group, comprising JNJ7777120, clozapine, isoloxapine,
UR-PI376 and clobenpropit, has similar potency at both the hH4R-F169V and the hH4R-
F168A mutant. These ligands contain bulky aromatic groups. The phenyl and chlorophenyl
moieties of clozapine and JNJ7777120, respectively, were suggested to occupy a hydrophobic
Table 1. [35S]GTPγS binding on hH4R wild-type, hH4R-F169V and hH4R-F168A mutant.
Ligand Parameter hH4R hH4R-F169V hH4R-F168A
histamine α 1 1 1
pEC50 8.13 ± 0.06 7.72 ± 0.07
●● 5.98 ± 0.06 ●●●
UR-PI294 α 1.02 ± 0.03 1.00 ± 0.07 0.91 ± 0.06
pEC50 8.35 ± 0.04 8.00 ± 0.11 6.78 ± 0.11
●●●
thioperamide α −1.39 ± 0.08 −0.63 ± 0.06 ●●● 0 ●●●
pEC50 6.58 ± 0.06 6.52 ± 0.05 n.a.
pKb 6.83 ± 0.05 7.97 ± 0.07
●●●
JNJ7777120 α −0.39 ± 0.03 0.43 ± 0.03 ●●● 0.20 ± 0.01 ●●●
pEC50 7.10 ± 0.08 6.21 ± 0.12
●● 6.40 ± 0.17
pKb 7.60 ± 0.05 6.17 ± 0.19
●●
VUF8430 α 0.84 ± 0.06 0.91 ± 0.06 0.69 ± 0.06
pEC50 7.42 ± 0.12 7.61 ± 0.07 5.74 ± 0.03
●●●
Immepip α 0.81 ± 0.03 0.85 ± 0.05 0.81 ± 0.02
pEC50 7.67 ± 0.05 7.73 ± 0.19 5.82 ± 0.11
●●●
clozapine α 0.67 ± 0.04 0.56 ± 0.03 0.40 ± 0.01 ●●
pEC50 6.24 ± 0.10 5.68 ± 0.12
● 5.38 ± 0.10 ●●
isoloxapine α 0.81 ± 0.03 0.85 ± 0.09 0.83 ± 0.07
pEC50 7.08 ± 0.13 6.36 ± 0.10
●● 6.10 ± 0.05 ●●●
UR-PI376 α 1.11 ± 0.08 0.49 ± 0.02 ●●● 0.39 ± 0.05 ●●●
pEC50 7.79 ± 0.08 6.25 ± 0.11
●●● 6.30 ± 0.15 ●●●
clobenpropit α 0.45 ± 0.04 0.27 ± 0.05 ● 0.14 ± 0.02 ●●
pEC50 7.65 ± 0.11 7.63 ± 0.15 7.40 ± 0.13
pKb 7.24 ± 0.06
pEC50-values ([
35S]GTPγS agonist mode), pKb-values ([
35S]GTPγS antagonist mode) and α (intrinsic activity, maximal effect relative to histamine = 1.0)
are given as mean ± SEM of at least three independent experiments, performed in triplicate. Results of statistical tests (one-way ANOVA and Bonferroni-
posthoc-tests): signiﬁcant differences with respect to hH4R-
● p < 0.05,
●● p < 0.01,
●●● p < 0.001.
In case of neutral antagonism (−0.25  α  0.25), pKb-values were considered for statistical analysis instead of pEC50-values. Maximal effect α = 0:
neutral antagonism. Data for hH4R and hH4R-F169V cf. Wiﬂing et al. [9].
doi:10.1371/journal.pone.0117185.t001
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pocket between TMs 3, 5, 6 and ECL2 [36, 37]. Most notably, MD simulations with
JNJ7777120 indicated that the chloro substituent is surrounded by a relatively tight pocket
formed by E163ECL2, F168ECL2, F169ECL2, L1755.39 and T3236.55 [38]. Mutations of these amino
acids, especially, affect binding modes directed towards ECL2. Affinity of ligands may be re-
duced due to loss of direct contacts and/or by distortion of the pocket. The binding mode of
clobenpropit is probably different, because of similar potency at the wild-type and
both mutants.
The second group, histamine, UR-PI294, VUF8430 and immepip, comprises rather small li-
gands devoid of hydrophobic substituents. Characteristic of this group is a significant decrease
in potency by about two orders of magnitude at the hH4R-F168A mutant compared to the wild-
type hH4R (Fig. 6A). By contrast, there were only minor effects on potency at the hH4R-F169V
mutant. Thus, F168 is probably involved in direct interactions with the ligands of this group.
The ligands of both groups are full or partial agonists, apart from JNJ7777120 at the wild-
type hH4R. According to docking on hH4R homology models, agonists as well as several antag-
onists and inverse agonists probably bind between TMs 3, 5, 6 and 7 via key interactions with
D943.32, E1825.46 and Q3477.42 [36–38]. Thioperamide is an exception as it binds only to inac-
tive hH4R state(s). By analogy, thioperamide is known to stabilize the inactive conformation of
the closely related hH3R. Molecular dynamics simulations of an hH3R-thioperamide complex
revealed a binding mode characterized by an extended conformation of the ligand, which is ori-
ented parallel to the membrane plane, an interaction of the imidazolyl moiety with tyrosine in
position 2.61, and the thiourea group positioned in the vicinity of F193, which corresponds to
F169 in the hH4R [39]. It may be speculated that thioperamide binds to the hH4R in the same
way, selectively contacting Y722.61 and F3447.39, whereas interactions with E1825.46 and
Q3477.42, proven essential in case of other H4R ligands, are precluded or only weak. Such a
binding mode would prevent the constriction of the orthosteric binding site (inward move-
ments of TMs 5, 6 and 7), characteristic of the conversion of the receptor to the active state
[23]. Direct interactions of thioperamide with F168 or F169 cannot be deduced from the data
in Table 1. The increase in pKb at the hH4R-F168A mutant by one order of magnitude com-
pared to the wild-type receptor is compatible with higher affinity of thioperamide to inactive
than to active state(s), represented by the mutant devoid of constitutive activity and the highly
constitutively active wild-type H4R.
Intrinsic activities of ligands and constitutive activity of receptors
The hH4R agonists histamine, UR-PI294, isoloxapine, VUF8430 and immepip did not show
significantly reduced intrinsic activities at both hH4R mutants compared to the wild-type,
whereas the maximal effects of clozapine, clobenpropit and UR-PI376 were diminished
(Fig. 6B). In case of inverse agonists, the reduced constitutive activity of the mutants is reflected
by lower maximal (inverse) responses. The partial inverse hH4R agonist JNJ7777120 was a par-
tial agonist at the mutant receptors. Thioperamide was a partial inverse agonist at hH4R-
F169V, the mutant with reduced constitutive activity, and a neutral antagonist at the hH4R-
F168A mutant, which is devoid of constitutive activity. The results support the hypothesis that
both F168 and F169 play a role in stabilizing an active state of the wild-type hH4R.
Constitutive activity [16] reflects a ligand-independent interconversion between inactive
and active receptor conformations. Interactions at the intracellular face involving the DRY
motif have been proven crucial for basal and agonist-induced receptor activation and signaling
[35, 40]. In case of the hH4R, which is devoid of the ionic lock, we demonstrated that interac-
tions close to the ligand binding pocket and ECL2 account for the high constitutive activity [9].
The mutation of F169 alone and, even more pronounced, the mutation of both F169 (ECL2)
ECL2 of the hH4R: Role in Ligand Binding and Constitutive Activity
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Figure 5. Concentration-response curves of ligands investigated in the [35S]GTPγS assay. All curves
are normalized with respect to the maximal effect of histamine (100%) at the respective receptor.
doi:10.1371/journal.pone.0117185.g005
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and S1795.43 (numbering according to the Ballesteros nomenclature [41]) into the correspond-
ing amino acids of the mouse and rat H4R orthologs (F169V, S179M, S179A) resulted in a
highly significant reduction of the constitutive activity [9].
The hH4R model in Fig. 7 suggests mutual effects of both phenylalanines, F168 and F169
(the FF motif), on the conformation of ECL2 [21]. Our present results with the hH4R-F168A
mutant support this idea. Compared to hH4R-F169V, which has still a low constitutive activity,
hH4R-F168A is completely devoid of constitutive activity. Accordingly, the single mutation of
either F169 into V and, especially, F168 into A weakens interactions within ECL2 and the sur-
rounding hydrophobic pocket consisting of amino acids as Y953.33, P166ECL2, L1755.39,
T1785.42, T3236.55, L3266.58, T333ECL3, and Y3407.35 (Fig. 7). Therefore, replacement of F168 or
Figure 6. Radar plots of potencies andmaximal effects at wild-type human H4R, hH4R-F169V and hH4R-F168Amutants. (A) pEC50 values (or pKb in
case of partial agonists/inverse agonists with −0.25 α 0.25). (B) maximal effects (α values, relative to histamine = 1).
doi:10.1371/journal.pone.0117185.g006
Figure 7. Binding pocket of the hH4R, homologymodel [9] based on the inactive state crystal
structure of the hH1R [24]. Nitrogens are colored in blue, oxygens in red and sulfurs in yellow. The carbons
are differently colored: the two cysteines forming the disulfide bond in yellow, the amino acids representing
the hydrophobic cluster in magenta, important amino acids for ligand binding in cyan and the two adjacent
phenylalanines forming the FF-motif in green.
doi:10.1371/journal.pone.0117185.g007
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F169 probably causes major conformational changes, which destabilize active and stabilize in-
active receptor states.
Conclusions
The present study demonstrates a highly significant influence of the hH4R-F168A mutant on
ligand binding as well as on constitutive activity, even surpassing the consequences of hH4R-
F169V mutation, revealing a key role of the FF motif for both, ligand-receptor interaction and
interconversion between inactive and active conformation of the wild-type hH4R. The results
may also be of relevance for other class A GPCRs comprising the FF motif, such as the β2AR,
the H3R and the M2R.
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